Workforce and Employment - As of October 31, 2024, the company employed approximately 17,900 people worldwide[81]. Financial Performance and Liquidity - The company’s cash and cash equivalents, along with cash generated from operations, are expected to satisfy liquidity requirements for at least the next twelve months[99]. - Research and development expenses decreased by 9% in 2024 compared to 2023, primarily due to lower expenses related to business exit activities and workforce reduction[97]. - The total share repurchase program for 2023 involved 8.4 million shares at a cost of $1,150 million, with remaining authorization of $2,000 million[100]. - The company has a stock repurchase program with a remaining authorization of $2,000 million for 2024[100]. Market Dynamics and Business Strategy - The life sciences and applied markets business is influenced by seasonality, with the first and fourth fiscal quarters typically delivering the strongest profits[94]. - The company is well diversified geographically to leverage local market opportunities and mitigate risks associated with weaknesses in any one region[98]. - The company is focused on expanding its position in developing countries and emerging markets as part of its growth strategy[103]. Product and Service Offerings - The diagnostics and clinical market focuses on providing instruments and software to understand biological processes and develop new therapeutic strategies[86]. - The company’s products include a wide range of technologies such as liquid chromatography, gas chromatography, mass spectrometry, and laboratory automation[87]. - The company’s consumables portfolio is designed to improve customer outcomes and is vendor neutral, allowing it to serve customers regardless of instrument purchase choices[82]. - Agilent CrossLab services are positioned to support a growing installed base of instruments, with a focus on digital and remote capabilities to enhance service quality[98]. - The environmental and forensics market utilizes the company's instruments for analyzing chemical pollutants and drug testing, serving various government and industrial customers[85]. - The diagnostics and clinical market aims to develop new therapeutic strategies and drugs, utilizing mass spectrometry technologies to identify and quantify metabolites and proteins[86]. Research and Development - Research and development expenses decreased by 9% in 2024 compared to 2023, primarily due to lower expenses related to business exit activities and workforce reduction[97]. - The academic and government market plays a significant role in technology adoption and therapeutic developments, influencing pharmaceutical and diagnostics companies[84].

Core Insights - Agilent Technologies' international operations are crucial for assessing its financial resilience and growth prospects [1][2] - The company's reliance on international markets is increasingly important for understanding its earnings sustainability and growth potential [2][3] Revenue Performance - Agilent's total revenue for the quarter was $1.7 billion, reflecting a 0.8% increase year-over-year [4] - International revenue trends show that Asia Pacific contributed $567 million (33.33%), a decrease of 4.56% from expectations [5] - Europe accounted for $454 million (26.69%), exceeding expectations by 11.52% [6] Future Projections - Analysts anticipate total revenue of $1.67 billion for the current fiscal quarter, with expected contributions of 35% from Asia Pacific ($584.07 million) and 27% from Europe ($451.01 million) [7] - For the full year, projected total revenue is $6.83 billion, a 4.9% increase from last year, with Asia Pacific and Europe expected to contribute 34.5% ($2.36 billion) and 25.6% ($1.75 billion) respectively [8] Strategic Considerations - The reliance on global markets presents both opportunities and challenges for Agilent, making the analysis of international revenue trends essential for forecasting future performance [9][10] - Analysts are closely monitoring these trends to refine earnings predictions, considering the impact of geopolitical factors and domestic market positions [10]

Core Insights - Agilent Technologies reported fourth-quarter fiscal 2024 earnings of $1.46 per share, exceeding the Zacks Consensus Estimate by 3.6%, and reflecting a year-over-year increase of 5.8% [1] - Revenues reached $1.70 billion, surpassing the Zacks Consensus Estimate by 1.67%, with a reported increase of 0.8% and a core basis decline of 0.3% compared to the previous year [1] Revenue Growth Drivers - Growth was primarily driven by advancements in the Pharmaceutical, Diagnostics, and Clinical sectors, along with improvements in the Chemical and Advanced Materials markets [2] - Challenges were noted in the Food, Academic and Government, and Environmental and Forensics markets during the reported quarter [2] Regional Performance - Modest weakening conditions in the Americas and China were significant headwinds, while growing momentum across Europe and the Asia Pacific provided a tailwind [3] Segment Performance - **Life Sciences & Applied Markets Group (LSAG)**: Generated $833 million, accounting for 49% of total revenues, with a 1% decline year-over-year on both reported and core basis due to softness in the instrument business, offset by strong demand for analytical lab consumables [5] - **Agilent Cross Lab Group (ACG)**: Revenues of $426 million, representing 25% of total revenues, grew 5% on both reported and core basis, driven by strong growth in contract business and Enterprise Services segment [6] - **Diagnostics and Genomics Group (DGG)**: Revenues decreased 1% year-over-year on a reported basis and 3% on a core basis to $442 million, accounting for 26% of total revenues, with expected softness in Cell Analysis and NASD, partially offset by growth in Cancer Dx and Genomics [7] Organizational Changes - The company unveiled a new organizational structure aimed at accelerating operational transformation and driving higher growth through a market-focused, customer-centric strategy [8] Operating Results - Gross margin in the LSAG segment contracted 40 basis points to 59.1%, while ACG's gross margin expanded 50 basis points to 50.9%, and DGG's gross margin contracted 220 basis points to 51.5% [9] - Non-GAAP operating margin for the fourth quarter was 27.4%, indicating a year-over-year contraction of 40 basis points [11] Expenses Overview - R&D expenses on a non-GAAP basis were $109 million, down 6% year-over-year, while SG&A expenses rose slightly to $362 million, marking a 1.4% increase [10] Balance Sheet & Cash Flow - As of October 31, 2024, cash and cash equivalents were $1.33 billion, down from $1.78 billion as of July 31, 2024, with accounts receivables at $1.32 billion [13] - Long-term debt increased to $3.35 billion from $2.14 billion in the prior quarter, with cash flow from operating activities at $481 million [14] Future Guidance - For Q1 fiscal 2025, management expects revenues of $1.650-$1.680 billion, indicating a decline of 0.5% year-over-year, with non-GAAP earnings per share expected to be $1.25-$1.28 [15] - For fiscal 2025, revenue guidance was revised to $6.79-$6.87 billion, implying a reported increase of 4.3-5.5% and a core increase of 2.5-3.5% from fiscal 2024 [16]

More than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specializing in niche markets, with strong growth potential, a solid management team, a sound capital allocation policy, and, most importantly, reasonable valuation. I do not chase quarterly results, nor do I follow the herd mentality. I do not use short-term stock performance as the measure of a company' ...

Financial Data and Key Metrics Changes - Agilent reported revenue of $1.701 billion for Q4 2024, reflecting a 1% increase year-over-year and flat core growth, with a sequential improvement of over 400 basis points from Q3 [14][35] - The company's earnings per share (EPS) for Q4 was $1.46, up 6% from the previous year, exceeding expectations [45] - Gross margin was 55.1%, down 70 basis points year-over-year, while operating margin was 27.4% [44] Business Line Data and Key Metrics Changes - Life Sciences and Applied Markets Group reported $833 million in revenue, a 1% decline due to constrained instrument volumes, although consumables grew mid-single digits [36] - Agilent CrossLab Group delivered revenue of $426 million, up 5%, with growth in every market except China [37] - Diagnostics and Genomics Group posted $442 million in revenue, representing a 3% decline, with solid growth in pathology offset by softness in NASD and cell-analysis instruments [39] Market Data and Key Metrics Changes - The largest end market, Pharma, declined 1%, with biopharma down mid-single digits and small molecule growing low-single digits [40] - Revenue in Chemicals and Advanced Materials grew 1%, driven by the semiconductor market [41] - Environmental and Forensics declined 6%, but PFAS solutions grew over 40% in Q4 [42] Company Strategy and Development Direction - Agilent announced a new market-focused organizational structure aimed at becoming more customer-centric and agile, part of its Ignite transformation program [16][31] - The company is focused on key growth vectors such as biopharma, PFAS, and Advanced Materials, with a commitment to innovation and customer-first strategies [30][32] - The acquisition of BIOVECTRA is expected to enhance Agilent's capabilities in therapeutic programs and expand its portfolio of CDMO services [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about steady market recovery and expects improvement throughout fiscal 2025, with a return to more traditional growth levels in the second half of the year [50][51] - The company anticipates modest growth in the Americas and Europe, with a conservative approach to revenue timing associated with stimulus in China [53] - Management highlighted the importance of the Ignite transformation in driving revenue growth and margin expansion [31][56] Other Important Information - Agilent achieved over $1 billion in digital orders for the first time in fiscal 2024, reflecting investments in its digital ecosystem [30] - The company returned over $400 million to shareholders in Q4, consisting of share repurchases and dividends [47] - Agilent was named Number 11 among Fortune's World's Best Workplaces 2024, highlighting its strong company culture [62] Q&A Session Summary Question: Instrument growth and replacement cycle expectations - Management noted a steady recovery in instruments with a book-to-bill ratio greater than one, indicating a positive outlook for the replacement cycle [68][69] Question: Expectations for China and stimulus orders - Management reported better-than-expected performance in China, with expectations for continued improvement and additional stimulus orders anticipated in Q1 [72][73] Question: Growth drivers in Diagnostics and Genomics Group - Management highlighted strong growth in pathology and a positive outlook for genomics, driven by differentiated value propositions and product traction [80][82] Question: Impact of tariffs on business - Management has diversified its supply chain to mitigate tariff impacts, estimating current exposure to be manageable [88][89] Question: Segment expectations for fiscal 2025 - Management provided guidance for low to mid-single-digit growth across various segments, with a focus on recovery in diagnostics and clinical markets [108][109]

Agilent Technologies (A) reported $1.7 billion in revenue for the quarter ended October 2024, representing a year-over-year increase of 0.8%. EPS of $1.46 for the same period compares to $1.38 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.67 billion, representing a surprise of +1.65%. The company delivered an EPS surprise of +3.55%, with the consensus EPS estimate being $1.41.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- ...

Agilent Technologies (A) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.41 per share. This compares to earnings of $1.38 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.55%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.25 per share when it actually produced earnings of $1.32, delivering a surprise of 5.60%.Over the last four qu ...

Exhibit 99.1 Agilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results Delivers solid results in Q4; initiates FY25 guidance Fourth-quarter fiscal year 2024 (1) • Revenue of $1.70 billion, up 0.8% reported and down 0.3% core from the fourth quarter of 2023. • GAAP net income of $351 million; earnings per share (EPS) of $1.22, down 25% from the fourth quarter of 2023. • Non-GAAP net income of $418 million; EPS of $1.46, up 6% from the fourth quarter of 2023. (2) Full fiscal year 2024 (1) • Revenue of ...

Agilent Technologies, Inc. A will release earnings results for the fourth quarter, after the closing bell on Monday, Nov. 25.Analysts expect Agilent to report quarterly earnings at $1.41 per share. That's up from $1.38 per share a year ago. The Santa Clara, California-based company projects to report quarterly revenue of $1.67 billion, compared to $1.69 billion a year earlier, according to data from Benzinga Pro.On Nov. 20, Agilent raised its quarterly dividend to 24.8 cents per share of common stock, a 5% ...

Agilent Technologies (A) is set to report fourth-quarter fiscal 2024 results on Nov. 25.For the fiscal fourth quarter, the company expects revenues of $1.641-$1.691 billion, suggesting a decline of 2.8-0.2% on a reported basis and 1.9-1.1% on a core basis from the year-ago quarter’s actuals.The Zacks Consensus Estimate for revenues is pegged at $1.67 billion, indicating a marginal decline of 0.86% from the year-ago quarter’s reported figure.Agilent’s non-GAAP earnings are expected to be $1.38-$1.42 per shar ...